Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 2, 2002 - Issue 6
Submit an article Journal homepage
30
Views
2
CrossRef citations to date
0
Altmetric
Review

Venous thromboembolism: implications for gene-based diagnosis and technology development

W Craig Hooper Hematologic Disease Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA. [email protected]
&
Christine De Staercke Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta GA, USA. [email protected]
Pages 576-586 | Published online: 09 Jan 2014

References

  • Virchow R. Phlogose und thrombose im. Gefassystem. Gessammelte Abhandlungen zur Wissenschaftlichen Medecin. Staatsdruckerei, Frankfurt, Germany, (1856).
  • Haire WD. Deep vein thrombosis and pulmonary embolus. In: Consultative Hemostasis and Thrombosis. Kitchens CS, Alving BM, Kessler CM (Eds), PA, USA, 197 (2002).
  • Esmon CT, Taylor EB, Snow ET Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb. Haemost. 66, 160–165 (1991).
  • •Discusses the relationship between inflammation and coagulation, provides new avenues of research that could have clinical application.
  • Cate JW, van der Poll T, Levi M et al Cytokines: trigger of clinical thrombotic disease. Thromb kkemost. 78, 415–419 (1997).
  • van Aiken BE, den Heijer M, Bos GMJ etal Recurrent venous thrombosis and markers of inflammations. Thromb. I-Lemost. 83, 536–539 (2000).
  • Esmon CT Cell mediated events that control blood coagulation and vascular injury. Ann. Rev. Cell. Biol. 9, 1–26 (1993).
  • Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl. Med 344, 1222–1231 (2001).
  • ?Provides a concise overview of venous thrombosis and genetic risk factors.
  • Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T A prospective study of the incidence of deep vein thrombosis within a defined urban population. j Intern. Med. 232, 155–160 (1992).
  • Anderson FA, Wheeler HB, Goldberg RJ eta]. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the DVT Word-rester study. Arch. Intern. Med. 151, 933–938 (1991).
  • Silverstein MD, Heit JA, Mohr DN eta]. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch. Intern. Med. 158, 585–593 (1998).
  • Kearon C, Salzman EW, Hirsh J. Epidemiology, pathogenesis and natural history of venous thrombosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RVV, Hirsh J, Marder VJ, °owes AW, George JN. PA, USA, 1153–1177 (2001).
  • Goldhaber SZ. Pulmonary embolism. N Engl. Med. 339, 93–104 (1998).
  • Goldhaber SZ. Pulmonary thromboembolism. In: Harrisoni Principles of Internal Medicine 1411 Edition. Fauci AS, Brauwald E, Isselbacher KJ etal, UK, 1469–1472 (1998).
  • Creager MA, Dzau VJ. Vascular diseases of the extremities. In: Harrisoni Principles of Internal Medicine 14th Edition. Fauci AS, Brauwald E, Isselbacher KJ et al, UK, 1398–1406 (1998).
  • Marchant-Kottke K. Genetic polymorphisms associated with venous and arterial thrombosis: an overview. Arch. Pathol Lab. Med. 126, 295–304 (2002). Provides information on known genetic variants and their relationship with cardiovascular disease.
  • Roberts HR, Tabares AH. Overview of the coagulation reactions, In: Molecular Basis of Thrombosis and limastasis. High KA, Roberts HR (Eds). NY, USA, 35–50 (1995).
  • Maim J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb. kkemost. 68(1), 7–13 (1992).
  • Heijboer H, Brandjes DPM, Buller HR, Stork A, Wouter Ten Cate J. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in out-patients with deep-vein thrombosis. N Engl. Med 323, 1512–1516 (1990).
  • De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 87(9), 3531–3544 (1996).
  • Cooper DN, Krawczak M. Protein C and protein C deficiency: In: Venous Thrombosis: from Genes to Clinical Medicine. Oxford, UK, 61–96 (1997).
  • •A monograph on the genetics of venous thrombosis.
  • Cooper DN, Krawczak M. Protein S and protein S deficiency: In: Venous Thrombosis: from Genes to Clinical Medicine. Oxford, UK, 97–117 (1997).
  • Bertina RM, Koeleman BP, Koster T etal Mutation in blood coagulation Factor V associated with resistance to activatedprotein C. Nature 369, 64–67 (1994).
  • Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gin mutation in Factor Va. Lancet 343, 1361–1362 (1994).
  • Gou D, Naipal A, Reitsma PH. World distribution of Factor V Leiden mutation (letter). Lancet 347,59 (1996).
  • Dzmiri N, Meyer B. World distribution of Factor V Leiden (letter). Lancet 347, 481–482 (1996).
  • Pepe G, Rickards 0, Vanegas OC eta]. Prevalence of Factor V Leiden mutation in non-European populations. Thromb. I-Lemost 77,329-331(1997).
  • Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 277, 1305–1307 (1997).
  • Austin H, Hooper WC, Dilley A eta]. The prevalence of two genetic traits related to venous thrombosis in Whites and African—Americans. Tropmb. Res. 86(5), 409–415 (1997).
  • Hooper WC, Dilley A, Ribeiro MJA et al A racial difference in the prevalence of the Arg506->G1n mutation. Thromb Res. 81, 577–582 (1996).
  • Rees DC, Cox M, Clegg JB. World distribution of Factor V Leiden. Lancet 346,1133–1134 (1995).
  • Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88, 3698–3703 (1996).
  • Dilley A, Austin H, Hooper WC et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks. Infants, patients with venous thrombosis, patients with myocardial infarction and control subjects.J. Lab. Clin. Med. 132,452-455 (1998).
  • Ehrenforth S, Ludwig G, Klinke S, Krause M, Scharrer I, Nowak-Gottl U. The prohtrombin 20210 A allele is frequently co-inherited in young carriers of the Factor V Arg 506 to Gln mutation with venous thrombophilia. Blood 91,2209–2210 (1998).
  • Zoller B, Svensson PJ, Dahlback B, Hillarp A. The 20210 allele of the prothrombin gene is frequently associated with the Factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. B/ooc/ 91,2210–2211 (1998).
  • Emmerich J, Rosendaal FR, Cattaneo M et al Combined effect of Factor V leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb. I-Lemost 86, 809–816 (2001).
  • Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of Factor V leiden and prothrombin 20210A on the risk of venous thromboembolism. Tropmb. I-Lemost. 86, 809–816 (2001).
  • De Stefano V, Martinelli I, Mannucci PM etal. The risk of recurrent deep vein thrombosis among heterozygous carriers of both Factor V Leiden and the G20210A prothrombin mutation. N Engl. I Med. 341,801-806 (1996).
  • •One of the first reports to document the importance of dual mutations for VTE recurrence.
  • Frosst P, Blom HJ, Milos R et a/. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Natuir Genet. 10,111–113 (1995).
  • Margaglione M, D'Andrea G, AAddedda M et al The methylenetetrahydrate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb. I-Lemost. 79,907-911 (1998).
  • Salden A, Keeney S, Hay CRM, Cumming AM. 'The C677T MTHFR variant and the risk of venous thrombosis'. BE J. Haematol 99,472 (1997).
  • Tosetto A, Missiaglia E, Frezzato M, Rodeghiero E The VITA Project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. BE .1. I-Lematol 97, 804–806 (1997).
  • Cattaneo M, Tsai MY, Bucciarelli P et al A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant Factor V (Factor V:Q506). Arterioscler. Thromb. Vascul Biol. 17,1662-1666 (1997).
  • Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84, 1031–1035 (1994).
  • Hooper WC, De Staercke C. The relationship between FV Leiden and pulmonary embolism. Respir Res. 3,8–11 (2002).
  • Spurr N, Darvasi A, Terrett J, Jazwinska L. New technologies and DNA resources for high-throughput biology. BE Med. 55, 309–324 (1999).
  • Day IN, Spanakis E, Palamand D, Weavind GP, O'Dell SD. Microplate-array diagonal-gel electrophoresis (MADGE) and melt-MADGE: tools for molecular-genetic epidemiology. Trends Biotechnol 16(7), 287–290 (1998).
  • Day IN, Humphries SE, Richards S, Norton D, Reid M. High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Bio Techniques 19(5), 830–835 (1995).
  • Holloway JW, Ye S, Day IN. Tools for molecular genetic epidemiology: a comparison of MADGE methodology with other systems. Biotechnol Genet. Eng. Rev 17,71–88 (2000).
  • Chen XH, O'Dell SD, Day IN. Microplate array diagonal gel electrophoresis for cohort studies of microsatellite loci. Bio7khniques 32(5)1080-1086 (2002).
  • Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the Factor V mutation associated with activated protein C resistance. Tropmb. I-Lemost. 74, 874–878 (1995). SiBowen DJ, Bowley S, John M, Collins PW. Factor V Leiden (G1691A), the prothrombin 3 --untranslated region variant (G20210A) and thermolabile methylenetetrahydrolfolate reductase (C677): a single genetic test genotypes all three loci-determination of frequencies in the S. Wales population of the UK. Thromb. I-Lemost 79,949–954 (1998).
  • Michelson KR. The application of capillary electrophoresis for DNA polymorphism analysis. In: Methods in Molecular Biology Mitchelson KR, Cheng J, Totowa NJ, USA, 3–26 (2001).
  • Benson J, Ellingsen D, Renshaw MA, Resler AG, Evatt BL, Hooper WC. Multiplex analysis of mutations in four genes using fluorescence scanning technology. Thromb. Res. 96,57–64 (1999).
  • Renshaw MA, Ellingsen D, Costner B, Benson J, Heit JA, Hooper WC. Fluorescent multiplex polymerase chain reaction analysis of four genes associated with impaired fibrinolysis and myocardial infarction. B/ooc/ Coagul Fibrinol 12,1–8 (2001).
  • Livak KJ. Allelic discrimination using fluorogenic probes and the 5 nuclease assay. Gene Analysis 14,143— 149 (1999).
  • Livak KJ, Flood SJA, Marmo J, Giusto W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful fordetecting PCR product and nucleic acid hybridization. PCR Meth. Appl 4,357–362 (1995).
  • Happich D, Schwaab, Hanfland P, Hoernschemeyer D. Allelic discrimination of Factor V leiden using a 5'nuclease assay. Thromb. Haemost. 82, 1294–1296 (1999).
  • Benson JM, Ellingsen D, Bonduris MK, Jenkins M, Dilley A, Hooper WC. Factor V and Factor V R2 allele; high-throughput analysis and association with venous thromboembolism. Thromb. I-Lemost. 86, 1188–1192 (2001).
  • Kwiatkowski RVV, Lyamichev N, de Arruda M, Neri B. Clinical, genetic and pharmacogenetic applications of the invader assay. Mal Diagn. 4,353–364 (1999).
  • Shi M. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Gun. Chem. 47, 164–172 (2001).
  • Benson JM, Phillips DJ, Holloway BP, Evatt BL, Hooper WC. Oligonucleotide ligation assay for detection of the Factor V mutation (Arg506->G1n) causing protein C resistance. Thromb. Res. 83,87-96 (1996).
  • Lay MJ, Wittwer CT Real-time fluorescence genotyping of Factor V Leiden during rapid-cycling PCR. Gun. Chem. 43, 2262–2267 (1997).
  • Schlatterer K, Orith M, Fitzner R, Tauber R. Genotyping of Factor V Leiden in research samples: a methodological comparison between allele-specific PCR (PCR-SSP) and the lightcycler technology. Biochemical, 31–34 (2000). http://biochem.roche.com
  • Ronaghi M, Karamohamed S, Petterson B, Uhlen M, Nyren P Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem. 242, 84–89 (1996).
  • Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat. 19,479–485 (2002).
  • Berg LM, Sanders R, Alderborn A. Pyrosequencinem technology and the need for versatile solutions in molecular clinical research. Expert Rev. Md. Diagn. 2, 361–369 (2002).
  • Fulton RJ, McDade RL, Smith PL eta]. Advanced multiplexed analysis with the FlowMetrixTM system. Gun. Chem. 43, 1749–1756 (1997).
  • Kuldin A. Munson K, Gjerde D, Haefele R, Taylor P. Detection of single-nucleotide polymorphisms with the Wave Tm DNA fragment analysis System. Genet. Test. 1, 201–206 (1997).
  • Xiao W, Oefner PJ. Denaturing High- performance Liquid Chromatography: areview. Hum. Mut. 17,439–474 (2001).
  • Spiegelman JL, Mindrinos MN, Oefner PJ. High-accuracy DNA sequence variation screening by DHPLC. BioTechniques 29, 1084–1090 (2000).
  • Talinai MR, Roberts SC, Dukek BA, Pruthi RK, Nicholas WL, Heit JA. Sensitivity and specificity of denaturing high-pressure liquid chromatography for unknown protein C gene mutations. Genet. Test. 5, 39–44 (2001).
  • Oldenburg J, Ivaskevicius V, Rost S et al Evaluation of DHPLC in the analysis of hemophilia A. J Biochem. Biophys. Meth. 47,39–51 (2001).
  • Xiao W, Stem D, Jain M, Huber CG, Oefner PJ. Multiplex capillary denaturing high-performance liquid chromotography with laser-induced fluorescent detection. BioTechniques 30,1332–1338 (2001).
  • Aydin A, Baron H, Bahring S, Schuster H, Luft FC. Efficient and cost-effective single nucleotide polymorphism detection with different fluorescent applications. BioTechniques 34,920–929 (2001).
  • White RII, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann. Int. Med. 128,737–740 (1998).
  • Martinelli I, Taioli E, Cetin I etal Mutations in coagulation factors in women with unexplained fetal loss. N Engl. J Med 343,913–916 (2000).
  • Greer I. Thrombosis in pregnancy: maternal and fetal issues. Lancet 353, 1258–1265 (1999).
  • Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. BE J 1-Lematol 114,512–528 (2001).
  • ••Provides guide to clinical testing and management of VTE.
  • Herrington DM, Vittinghoff E, Howard TD et al Factor V Leiden, hormone replacement therapy and risk for venous thromboembolic events in women with coronary disease. Arterioscler. Thromb. Vasc. Biol. 22,1012–1017 (2002).
  • Bauer K. Hormone replacement therapy and the Factor V Leiden mutation (editoral). Arterioscler. Thromb. Vasc. Biol. 22,879–880 (2000).
  • Rossouw JE, Anderson GL, Prentice RL et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the women's health initiative randomized controlled trial. JAMA 288,321–333 (2002).
  • Higashi MK, Veensta DL, Kondo LM etal Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAIVIA 287,1690–1698 (2002).
  • Younis JS, Ohel G, Brenner B eta]. The effects of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss association with Factor V Leiden mutation. Br. Obset. Gynocol 107, 415–419 (2000).
  • Greaves M, Baglin T Laboratory testing for heritable thrombophilia: impact of clinical management of thrombotic disease. BE J 1-Lematol 109,699–703 (2000).

Websites

  • Check W Mutations add up to thrombotic risk. CAP TODAY: January (2002) www.cap.org/captoday/archive/2002/ mutations_cover.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.